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Antimycotic perfusion through Candida biofilms was demonstrated by a modification of a simple in vitro
diffusion cell bioassay system. Using this model, the perfusion of three commonly used antifungal agents,
amphotericin B, fluconazole, and flucytosine, was investigated in biofilms of three different Candida species
(i.e., Candida albicans, Candida parapsilosis, and Candida krusei) that were developed on microporous filters.
Scanning electron microscopy revealed that C. albicans formed a contiguous biofilm with tightly packed
blastospores and occasional hyphae compared with C. parapsilosis and C. krusei, which developed confluent
biofilms displaying structural heterogeneity and a lesser cell density, after 48 h of incubation on nutrient agar.
Minor structural changes were also perceptible on the superficial layers of the biofilm after antifungal
perfusion. The transport of antifungals to the distal biofilm-substratum interface was most impeded by C.
albicans biofilms in comparison to C. parapsilosis and C. krusei. Fluconazole and flucytosine demonstrated
similar levels of perfusion, while amphotericin B was the least penetrant through all three biofilms, although
the latter appeared to cause the most structural damage to the superficial cells of the biofilm compared with
the other antifungals. These results suggest that the antifungal perfusion through biofilm mode of growth in
Candida is dependent both on the antimycotic and the Candida species in question, and in clinical terms, these
phenomena could contribute to the failure of Candida biofilm-associated infections. Finally, the in vitro model
we have described should serve as a useful system to investigate the complex interactions that appear to
operate in vivo within the biofilm-antifungal interphase.
Candida species are opportunistic pathogens which cause
superficial and systemic disease in compromised individuals
(26). Candida albicans is the main causative agent of oropha-
ryngeal candidiasis, while the clinical significance of other
non-C. albicans species such as Candida parapsilosis and Can-
dida krusei are being increasingly recognized (16, 24, 28). The
first step in the pathogenesis of candidal infection entails the
adhesion of the yeast to the host surface or an associated
prostheses, such as a denture or intravascular catheter material
(18, 27, 34). It is thought that the presence of an indwelling
denture or a catheter modifies the normal planktonic mode of
growth of the yeasts in a yet unknown manner to a sessile
biofilm mode of growth, leading to a structured community of
cells encased in an extracellular polymer matrix. Once the
biofilm mode of growth is established on prostheses such as
heart valves and surgical implants (17, 19), the sessile yeasts
begin to display unique characteristics, including resistance to
antifungal agents (6). This in turn leads to failure of antifungal
therapy and chronic infection, remediated by surgery and/or
removal of these devices (33). Factors thought to contribute to
antimycotic resistance in Candida biofilms include the growth
rate of the yeast (2) and the low diffusion gradient of the
antimicrobial through the extracellular polymer matrix of the
biofilm (2, 3).
Although there are many reports on the phenomenon of
incomplete penetration of antimicrobial agents through bacte-
rial biofilms (1, 31, 32, 35), none so far have investigated this
particular feature in Candida biofilms. Therefore, the main
objective of the present study was to evaluate qualitatively the
antifungal perfusion in Candida biofilms with a modified, novel
assay system. For this purpose, we used a representative isolate
of each of C. albicans, C. parapsilosis, and C. krusei and three
common antifungals: amphotericin B, fluconazole, and flucy-
tosine. In addition, ultrastructural features were evaluated by
scanning electron microscopy (SEM) to visualize and compare
the cellular damage to the superficial layers of the Candida
biofilm before and after antifungal perfusion.
MATERIALS AND METHODS
Candida strains. Three Candida strains used in this study were C. albicans
HK1Sa, from a human immunodeficiency virus-infected patient in Hong Kong,
and C. parapsilosis ATCC 22019 and C. krusei ATCC 6258, from the American
Type Culture Collection. The identity of all three strains were reconfirmed by
using the API20C AUX system, germ tube formation, and the CHROM agar
technique prior to the experiments. All three Candida strains were maintained
on Sabouraud’s dextrose agar slopes at 4°C.
To prepare the yeast inoculum for the development of biofilms, a loopful of
the candidal strain under investigation was transferred into 10 ml of liquid yeast
nitrogen base (YNB; Difco) supplemented with 50 mM galactose and incubated
at 37°C overnight on a rotary shaker at 75 rpm. Cells were harvested and washed
with phosphate-buffered saline (PBS; pH 7.2), and a cell suspension of approx-
imately 107 CFU/ml was prepared by using a spectrophotometer (at 520 nm).
Two types of agar media were used. First, Sabouraud’s dextrose agar supple-
mented with 500 mM galactose was used for the development of biofilms, and
second, Sabouraud’s dextrose agar supplemented with both 500 mM galactose
and the specific antimycotic agent was used for the antifungal penetration studies
(see below).
Antifungals. Three antifungals commonly used to treat oropharyngeal and
systemic candidiasis were selected for the study, viz., amphotericin B (Sigma),
fluconazole (Pfizer), and flucytosine (Sigma). Three concentrations of the drugs,
i.e., 150, 300, and 600 g/ml were prepared for each antifungal. Stock solutions
of the drugs in dimethyl sulfoxide (amphotericin B), dimethyl formamide (flu-
conazole), and sterile distilled water (flucytosine) were prepared prior to use and
* Corresponding author. Mailing address: Dean’s Office, Faculty of
Dentistry, University of Hong Kong, 34 Hospital Rd., Hong Kong,
SAR, People’s Republic of China. Phone: 852 2859 0480. Fax: 852 2547
6133. E-mail: lakshman@hku.hk.
818
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
added to a YNB–500 mM galactose agar solution at a temperature of 40°C for
the preparation of the nutrient agar plates, which were then stored at 4°C and
used within 1 day.
Development of Candida biofilms for antifungal penetration studies. Candida
biofilms were developed on Isopore membrane filters (diameter, 25 mm; pore
size, 12 m; Millipore) by using a modification of a method described by Anderl
et al. (1). A schematic presentation of this method is shown in Fig. 1. At first the
filter membranes were sterilized by exposure to UV light (15 min per side), and
each membrane was aseptically placed on a Sabouraud’s dextrose agar (500 mM
galactose) plate. Afterwards, 50 l of an overnight Candida inoculum (107
CFU/ml) was carefully deposited on the membrane with a pipette. The nutrient
agar plates with the inoculum were incubated at 37°C for 1 h (to dry the deposit),
and then the plate was inverted and reincubated at 37°C for a period of 48 h.
During this incubation period, each filter with the growing biofilm was manually
lifted and repositioned on a fresh location on the plate every 10 to 12 h.
After 48 h, the biofilms on the membrane filters were placed on an antibiotic-
incorporated agar medium prepared as described above with the biofilm facing
outwards. Black microporous membrane filters (diameter, 13 mm; pore size, 0.2
m; Millipore) were then placed on top of 48-h-old Candida biofilms. A blank
antibiotic (AB) disk (diameter, 9 mm; Difco) moistened with 10 l of PBS (pH
7.2) was then placed on top of the 13-mm-diameter membrane (wetting the disk
obviates passive capillary perfusion of the antifungal through the biofilm). The
whole assembly was then incubated at 37°C for 4 h (Fig. 1).
A semiquantitative evaluation of the antifungals that diffused into an AB disk
through the biofilm was performed as follows, with C. parapsilosis as an indicator
organism. The disk was removed after the specified incubation time and placed
on a fresh RPMI agar plate spread plated with 100 l of (planktonic) C. parap-
silosis. For this assay, C. parapsilosis was grown on Sabouraud’s dextrose agar at
37°C, and the growth was diluted with PBS to an optical density of 0.05 (at 520
nm) prior to plating. The control used for the experiment was an AB disk placed
on the two-membrane system devoid of a biofilm. Then the RPMI plates were
incubated at 37°C for 24 h, and the diameters of the growth inhibition zones
(with and without biofilms) were measured by a computerized image analysis
system (Quantimet 500 Qwin; Leica, Cambridge, United Kingdom). The assay
was conducted in duplicate on three separate occasions for each Candida strain
tested.
Standard curves for antifungal concentration versus zone of inhibition. Stan-
dard curves of the drug concentration versus the radius of growth inhibition of
the indicator organism for amphotericin B, fluconazole, and flucytosine were
constructed by using the methodology described above.
FIG. 1. (A) Schematic representation of the experimental system used to monitor antifungal penetration through Candida biofilms. The biofilm
(a) was developed on a 25-mm-diameter microporous polycarbonate membrane (b) resting on the agar medium. A 13-mm-diameter microporous
polycarbonate membrane (c) was placed on top of the biofilm, and then a moistened antibiotic disk (d) was placed on top of the polycarbonate
membrane. The entire unit (components a through d) was then transferred to antifungal-laced agar (e). (B) Transverse view of the Isopore filter
membrane placed on YNB–500 mM galactose agar and a surface view of the Isopore membrane inoculated with the yeast suspension (method
adapted from Anderl et al. [1]).
FIG. 2. Standard curves for the three antifungal agents, showing
the relationship between drug concentration and the radius of growth
inhibition of a lawn of C. parapsilosis on RPMI agar. 5FC, flucytosine;
FL, fluconazole; AmB, amphotericin B.
VOL. 43, 2005 DIFFERENTIAL ANTIFUNGAL PERFUSION IN CANDIDA BIOFILMS 819
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
SEM. For SEM, biofilms were developed on microporous filters for 4, 9, 19,
and 24 h, as described earlier. The biofilms were then rinsed in (4% [vol/vol]
formaldehyde, 1% [vol/vol] phosphate buffer) and placed in 1% osmium tetrox-
ide for 1 h. Samples were subsequently washed in distilled water, dehydrated in
a series of ethanol washes (70% for 10 min, 95% for 10 min, and 100% for 20
min), and air dried in a desiccator prior to sputter coating with gold. Afterwards,
the surface topographies of biofilms were visualized with a scanning electron
microscope (Philips XL30CP) in high-vacuum mode at 10 kV, and the images
were processed for display with Photoshop software (Adobe Systems, Inc.,
Mountain View, Calif.).
Statistics. The Kruskal-Wallis test was used to determine (i) significant dif-
ferences in diffusion of the three concentrations of each of the drugs with each
of the three Candida species and (ii) significant differences between a single
Candida species and a similar concentration of the three respective drugs. The
Mann-Whitney U test was used to compare significant differences between the
control and each single drug concentration for each of the Candida species.
RESULTS
Methodology. All three Candida species evaluated devel-
oped satisfactory biofilms on membrane filters, and the whole
assembly could be easily detached from the substrate surface
for the diffusion studies. The use of the AB disk with the
antifungal and the antifungal sensitivity assay with C. parapsi-
losis as the indicator organism yielded reproducible results on
repeat experiments conducted on separate occasions, indicat-
ing satisfactory sensitivity of the assay system.
Standard curves for antifungal concentration versus zone of
inhibition. Standard curves of the drug concentration versus
the radius of growth inhibition of the indicator organism for
the three antifungals were constructed as shown in Fig. 2.
However, these standard curves were curvilinear and hyper-
bolic, indicating that the radius of growth inhibition could be
used to derive the perfusion of only the very low drug concen-
trations. For instance, amphotericin B and flucytosine showed
a concentration-dependent difference in the range of 10 to 100
g/ml, while fluconazole exhibited a slightly higher range of 10
to 220 g/ml. Therefore, the percent inhibition of drug pene-
tration for each experiment was expressed in a semiquantita-
TABLE 1. Percent drug penetration of the three antifungals through the three different Candida biofilms compared with
biofilm-free controlsa
Candida species Drug
% Penetration (SD) at concn (g/ml):
P valueb
150 300 600
C. albicans Amphotericin B 0.00 (0.00) 0.35 (0.05) 2.02 (0.72) 0.027
Fluconazole 55.98 (4.57) 60.80 (6.12) 65.36 (4.42) 0.275
Flucytosine 51.62 (6.94) 59.14 (7.91) 67.86 (6.66) 0.045
C. parapsilosis Amphotericin B 0.00 (0.00) 1.28 (0.27) 1.68 (0.45) 0.027
Fluconazole 63.81 (7.40) 74.64 (2.45) 86.87 (3.86) 0.037
Fluocytosine 67.53 (12.50) 79.27 (12.04) 87.99 (5.59) 0.037
C. krusei Amphotericin B 0.00 (0.00) 1.14 (0.32) 2.02 (0.72) 0.027
Fluconazole 95.99 (12.27) 92.31 (3.08) 91.92 (3.33) 0.346
Flucytosine 87.43 (12.89) 89.92 (12.63) 89.30 (7.59) 0.346
a Calculations were made, using the radii of growth inhibition zones, of lawns of C. parapsilosis grown of RPMI agar.
b Kruskel-Wallis H test.
FIG. 3. Penetration of various concentrations (i.e., 150, 300, and 600
g/ml) of the three antifungals, amphotericin B (a), fluconazole (b),
and flucytosine (c), through 48-h-old C. albicans, C. parapsilosis, and C.
krusei biofilms shown in terms of the radii of growth inhibition zones
on a lawn of C. parapsilosis on RPMI agar.
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tive manner by using data obtained with a corresponding con-
trol AB disk without a biofilm (Table 1).
Antifungal perfusion. The variations in antifungal perfusion
in the three different Candida biofilms for the three antimy-
cotics studied were quantified in terms of the zone of inhibition
of an indicator organism (C. parapsilosis) on RPMI agar. Sta-
tistical analysis revealed significant differences in drug pene-
tration through the three different Candida biofilms for each of
the drug concentrations tested (P  0.05) (Fig. 3).
Amphotericin B. When the permeation of amphotericin B
through the three different Candida biofilms was compared, a
statistically significant reduction in drug diffusion was noted for
all three Candida species for the 150-g/ml concentration of
the drug (P 0.037). However, 300-g/ml amphotericin B was
inhibited significantly only by C. albicans (P  0.046), while at
a higher concentration of this drug, its penetration was signif-
icantly inhibited by C. parapsilosis (P 0.05) and C. albicans (P
 0.046) but not by C. krusei (P  0.346) (Fig. 3a).
Fluconazole. The profile of fluconazole penetration through
the biofilms was noted to be different than that of either am-
photericin B or flucytosine. Thus, fluconazole permeation
through C. albicans biofilms was significantly lower for all of
the tested drug concentrations (P  0.05), while C. parapsilosis
exhibited a significant difference only for 150 and 300 g/ml (P
 0.05) and C. krusei exhibited a significant difference only for
150 g/ml (P  0.05). This implied that the C. albicans biofilm
was the most resistant to fluconazole perfusion. However, with
increasing concentrations of fluconazole, a corresponding sig-
nificant increase in drug perfusion (P  0.05) was seen with all
three Candida biofilms (Fig. 3b).
Flucytosine. For C. albicans, flucytosine did not demonstrate
a significant difference in drug perfusion with either a 150-,
300-, or 600-g/ml concentration compared with the control
biofilm (P  0.05). A similar trend in drug perfusion was
observed for both C. parapsilosis and C. krusei biofilms. How-
ever, as observed for fluconazole, all three Candida biofilms
demonstrated a significant increase in drug perfusion (P 
0.05) with increasing flucytosine concentrations (Fig. 3c).
Ultrastructural features. The ultrastructure of biofilm ma-
trix observed through SEM varied depending on the Candida
species investigated. Thus, C. albicans produced a more pro-
fuse biofilm relative to the two less commonly pathogenic C.
parapsilosis and C. krusei. The latter two species first developed
a basal blastospore cell layer sparsely dispersed on the filter
surface devoid of either pseudohyphae or hyphae, whereas C.
albicans essentially developed into a more contiguous biofilm
intimately packed with blastospores and occasional pseudohy-
phae after 4 h of growth (Fig. 4A). Also, during the early phase
of biofilm growth, C. parapsilosis cells adhered in relatively
large numbers compared to C. krusei. These cells then gradu-
ally grew and developed a denser structure (at 7 h) mainly
composed of noncontiguous small blastospore aggregates and
channels in between (Fig. 4B and C). Both C. parapsilosis and
C. krusei biofilms at this stage were less densely packed than C.
FIG. 4. SEM images of the Candida biofilms on polycarbonate microporous filters (diameter, 25 mm; pore size, 12 m; Millipore). (A) C.
albicans at 4 h; (B) C. parapsilosis at 7 h; (C) C. krusei at 7 h; (D) C. albicans at 7 h.
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albicans (Fig. 4D) and were devoid of extracellular polymeric
material.
After 19 h of growth, C. albicans exhibited a multilayer
biofilm structure with a few hyphae penetrating the matrix
(Fig. 5A). However, even after 24 h, extracellular polymeric
material could not be visualized in C. albicans biofilms, which
at this stage was 12 to 15 cell layers thick (Fig. 5B). C. parap-
silosis and C. krusei also developed confluent biofilms after
approximately 24 h. Characteristically, the latter two species
displayed structural heterogeneity with a lesser cell density
(Fig. 5C and D) and channels traversing the cell mass than C.
albicans.
Visualization of the ultrastructure in general revealed that
the most damage to the biofilm constituents was caused by the
highest concentrations of the three antifungals. However, am-
photericin B caused the most extensive damage, especially to
the most superficial cell layers of all three Candida biofilms,
compared to fluconazole and flucytosine (Fig. 6, 7, and 8).
Amphotericin B-treated sessile C. albicans cells demonstrated
a range of changes, such as shrinkage of cells, ballooning blas-
tospores, ruptured cell walls, and shrunken, wrinkled, or fused
Candida blastospores. This suggests that despite the relative
minimal diffusion, amphotericin B, compared with other drugs,
may be exerting a fairly severe metabolic interference in Can-
dida biofilms. Amphotericin B-perfused C. parapsilosis cells
also demonstrated a high degree of destruction with ruptured
and shrunken cells, while C. krusei blastospores exhibited the
least damage.
The effect of fluconazole perfusion was more subtle. Effects
of this drug were barely noticeable with C. albicans biofilms,
whereas a small number of distorted cells were seen in the C.
parapsilosis and C. krusei biofilms, especially on the superficial
layers.
DISCUSSION
The development and characterization of Candida biofilms
on bioprosthetic surfaces that are components of indwelling
devices are well documented (5, 13, 14, 23). These studies have
shown that Candida biofilm development is closely associated
with the generation of an extracellular matrix and that mature
biofilms show a highly heterogeneous structure and grow vari-
ably depending on the topography of the substrate. It has also
been shown that C. albicans forms larger and more complex
biofilms on silicone elastomer catheter material than C. parap-
silosis, Candida pseudotropicalis and Candida glabrata and that
differences occur between invasive and noninvasive Candida
isolates from infective foci (12, 14).
It is now recognized that antibiotic resistance is a general
trait associated with biofilm organisms, including bacteria (21,
22) and fungi (15, 23). Several theories have been proposed to
explain this phenomenon, including the growth rate differen-
FIG. 5. SEM images showing the biofilm architecture of different Candida biofilms on polycarbonate microporous filters (diameter, 25 mm;
pore size, 12 m; Millipore). (A) C. albicans at 19 h; (B) C. albicans at 24 h; (C) C. parapsilosis at 24 h; (D) C. krusei at 24 h. Note the lesser cell
density of the latter two species than that of C. albicans.
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FIG. 6. SEM images of 48-h C. albicans HK1Sa. (A) Control C.
albicans HK1Sa; (B) C. albicans HK1Sa biofilm exposed to 600-g/ml
amphotericin B for 4 h; (C) C. albicans HK1Sa biofilm exposed to
600-g/ml fluconazole for 4 h. Note the wrinkled, shrunk, ruptured,
and ballooning effect of the drug on yeast cells.
FIG. 7. SEM images of 48-h C. parapsilosis ATCC 22019. (A) Con-
trol; (B) C. parapsilosis ATCC 22019 biofilm exposed to 600-g/ml
amphotericin B for 4 h; (C) C. parapsilosis ATCC 22019 biofilm ex-
posed to 600-g/ml fluconazole for 4 h. Note the ruptured and
shrunken effect of the drug on yeast cells.
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tials (9, 10), a recalcitrant phenotypic state (4), the production
of antibiotic-degrading enzymes (11), and the extracellular
polymeric material that may act as an adsorbent or a reactant
with the antimicrobial (30). Most of the foregoing studies, up to
now, have been conducted with bacterial biofilms, and sparse
information is available on the diffusion parameters of antimy-
cotics in Candida biofilms. For instance, Baillie and Douglas ob-
served that 20 times the MIC of commonly used antifungals such
as amphotericin B, fluconazole, or flucytosine is required to cause
a significant reduction in cell numbers (2). Further Chandra et al.
(6) reported that C. albicans required low MICs of polyenes and
fluconazole during the early biofilm development phase. How-
ever, during biofilm maturation, they became highly resistant to
these drugs. These studies are hampered by the lack of an appro-
priately standardized model system to evaluate drug diffusion in
candidal biofilms, and the present model was an attempt to ad-
dress this issue. The advantages of such an in vitro membrane-
supported biofilm system are (i) flexibility to investigate antifun-
gal resistance by using simultaneous and parallel biofilm samples,
(ii) the accessibility to both sides of the biofilm, after its removal
from the membrane surface, and (iii) the possibility of using these
biofilms as primitive models of pseudomembranous candidal in-
fections. In our hands, we found this system to be relatively sim-
ple, inexpensive, and reliable for measurement of the qualitative
differences in antifungal perfusion through Candida biofilms.
Our SEM studies revealed that the biofilms on micropore
filters were distinct from those on polymethyl methacrylate
strips or silicone elastomer disks, as reported by previous work-
ers (5, 14). For instance, we observed large numbers of C.
albicans microcolonies on the filter surface after only 4 h of
incubation, unlike the smaller numbers that appeared during a
similar incubation period with acrylic strips (5). There were
only extremely sparse hyphal forms of C. albicans in mature
filter surface biofilms, in comparison to profuse filamentation
seen on polymethyl methacrylate strips (5), silicone elastomers
(14), or polyvinyl chloride surfaces (13). This anomaly may be
due to strain variation in germ tube and hyphal development
(8, 25), and further studies with multiple Candida strains with
the present system are required to confirm our findings.
Upon prolonged incubation, C. albicans biofilms developed
into a dense mass stacked in a palisadic manner devoid of intra-
cellular spaces. It is tempting to speculate that this exuberant
growth mode may easily retard antifungal penetration into the
basal layers of the biofilms, thus protecting them from the drug
action. We also noted that C. albicans biofilms developed barely
discernible matrix material under static incubation on nutrient
agar plates, an observation similar to that of Hawser et al. (13).
In addition to C. albicans, we also used C. parapsilosis and C.
krusei strains for the present pilot studies. The latter, in par-
ticular, exhibits intrinsic resistance to azoles, and to our knowl-
edge, no one has evaluated its biofilms. Interestingly, the C.
parapsilosis biofilms that were developed resembled their
counterparts on polymethyl methacrylate disks cultured in
YNB medium, where the yeast form was predominant (5).
Compared with C. albicans, sparse numbers of C. parapsilosis
and C. krusei microcolonies were seen on the filter surface
after 4 h, and these slowly developed into less-dense biofilms,
mostly of blastospores, during the ensuing 48-h period. When
compared with C. albicans, these biofilms were of reduced
thickness, less profuse, and devoid of hyphal elements.
FIG. 8. SEM images of 48-h C. krusei ATCC 6258. (A) Control C.
krusei ATCC 6258; (B) C. krusei ATCC 6258 biofilm exposed to 600-
g/ml amphotericin B for 4 h; (C) C. krusei ATCC 6258 biofilm
exposed to 600-g/ml fluconazole for 4 h.
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When we evaluated antifungal perfusion in 48-h biofilms, it
was noted that amphotericin B was likely to be the least pen-
etrant through the biofilms of all three Candida species com-
pared with fluconazole and flucytosine, both of which demon-
strated almost a similar degree of drug penetration. However,
further kinetic analyses have to be performed to confirm this
data. One reason for the foregoing observation could be the
large size of the amphotericin B molecule compared with flucy-
tosine and fluconazole (20), which may hinder its diffusion.
Another could be the hydrophobicity of amphotericin B, which
lowers its solubility and, hence, its biofilm perfusion (7). Al-
though, of the tested antifungals, amphotericin B was the least
penetrant through the three Candida biofilms, SEM observa-
tions revealed that it caused the most damage to the biofilm
surface layer in comparison to fluconazole and flucytosine.
In general, biofilms are encased within an exopolymer matrix
which may restrict the diffusion of solutes and also bind anti-
microbials. For example, extracellular polysaccharide matrices
of bacterial biofilms are known to differentially regulate the
diffusion of antibiotics (29). Stewart et al. (30) observed that
chlorosulfamate penetrated bacterial biofilms more rapidly
than hypochlorite due to a slower reaction rate with biofilm
constituents. On the other hand, the ability of an antibiotic to
penetrate the biofilm can be severely retarded if the antimi-
crobial agent is neutralized by its reactivity with the biofilm
(30). These observations suggest that the extent of antibiotic
penetration through bacterial biofilms is agent and organism
specific, and it is likely that similar conditions may operate in
candidal biofilms.
In conclusion, the results of our study indicate that the
ultrastructure of different Candida biofilms is species specific,
varies considerably, and may be affected by the substrate con-
tents. The major differences in the spatial configurations of the
three different Candida biofilms seen in our SEM images tend
to suggest that genes encoding biofilm formation may be dif-
ferentially regulated during this mode of growth. Finally, the
present method appears to be simple and versatile for the
study of differential perfusion of antifungals or other solutes
through the biofilms of various Candida species. In clinical
terms, it is difficult to determine if this type of in vitro biofilm
morphology we observed resembles in vivo candidiasis on mu-
cosal surfaces, inert catheters, or denture surfaces. Further
studies with a large number of clinical Candida strains with the
proposed method are required to demystify the complexities
associated with the biofilm-solute interphase.
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